Dicer1 Depletion Leads to DNA Damage Accumulation and Cell Death in a RET/PTC3 Papillary Thyroid Cancer Mouse Model, Thereby Inhibiting Tumor Progression

dc.contributor.authorRojo-Pardillo, Maria
dc.contributor.authorAugenlicht, Alice
dc.contributor.authorDom, Geneviève
dc.contributor.authorKero, Jukka
dc.contributor.authorRobaye, Bernard
dc.contributor.authorMaenhaut, Carine
dc.contributor.organizationfi=lastentautioppi|en=Paediatrics and Adolescent Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.40612039509
dc.converis.publication-id504540090
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/504540090
dc.date.accessioned2026-01-21T12:35:38Z
dc.date.available2026-01-21T12:35:38Z
dc.description.abstractBeyond well-known genetic drivers, microRNA dysregulation has emerged as a key contributor to thyroid tumorigenesis. Central to this process is Dicer1, a ribonuclease essential for microRNA maturation, whose expression is often reduced in papillary thyroid carcinoma (PTC). Evidence from previous studies suggest Dicer1 functions as a context-dependent haplo-insufficient tumor suppressor gene: partial loss may promote tumor development, whereas complete loss may disrupt essential cellular functions, causing cell death and tumor suppression. However, the effects of partial or complete Dicer1 loss in thyroid cancer remain unclear. To explore this, we genetically inactivated one (heterozygous) or both (homozygous) Dicer1 alleles specifically in thyroid follicular cells of a RET/PTC3 transgenic mouse model using an inducible Cre-Lox system. Our findings deepen the current understanding of the RET/PTC3-driven PTC model by revealing an increased number of vimentin-positive cells and disruption in redox homeostasis. Additionally, whereas heterozygous Dicer1 loss did not alter tumor progression in RET/PTC3 mice, total loss reduced tumor growth and led to accumulated DNA damage and cell death. These findings highlight the crucial role of Dicer1 dosage in thyroid cancer progression and underscore its potential as a therapeutic target for aggressive PTC and other malignancies characterized by aberrant Dicer1 expression.
dc.identifier.eissn2073-4409
dc.identifier.jour-issn2073-4409
dc.identifier.olddbid212710
dc.identifier.oldhandle10024/195728
dc.identifier.urihttps://www.utupub.fi/handle/11111/53143
dc.identifier.urlhttps://doi.org/10.3390/cells14181465
dc.identifier.urnURN:NBN:fi-fe202601216069
dc.language.isoen
dc.okm.affiliatedauthorKero, Jukka
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherMDPI AG
dc.publisher.countrySwitzerlanden_GB
dc.publisher.countrySveitsifi_FI
dc.publisher.country-codeCH
dc.relation.articlenumber1465
dc.relation.doi10.3390/cells14181465
dc.relation.ispartofjournalCells
dc.relation.issue18
dc.relation.volume14
dc.source.identifierhttps://www.utupub.fi/handle/10024/195728
dc.titleDicer1 Depletion Leads to DNA Damage Accumulation and Cell Death in a RET/PTC3 Papillary Thyroid Cancer Mouse Model, Thereby Inhibiting Tumor Progression
dc.year.issued2025

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Kero_etal_dicer1_2025.pdf
Size:
5.87 MB
Format:
Adobe Portable Document Format